⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7532013 | 0.78 | ALDH1A1 (0.37) | — | |
| SCHEMBL3277949 | 0.70 | LMNA (0.33) | — | |
| SCHEMBL2039720 | 0.70 | — | — | |
| SCHEMBL11700649 | 0.66 | GPR35 (0.33) | — | |
| SCHEMBL1136675 | 0.61 | TDP1 (0.45) | — | |
| SCHEMBL2193445 | 0.61 | LMNA (0.33) | — | |
| SCHEMBL11882483 | 0.61 | ALDH1A1 (0.33) | — | |
| SCHEMBL5604304 | 0.60 | LMNA (0.31) | — | |
| SCHEMBL7136437 | 0.58 | TDP1 (0.46) | — | |
| SCHEMBL33832 | 0.58 | TDP1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2571362-A1 | IMPROVED PROCESS FOR A FOLATE-TARGETED AGENT | Endocyte, Inc. (US) | 2013-03-27 | — | — | EP | claimed |
| US-20130065841-A1 | PROCESS FOR A FOLATE-TARGETED AGENT | ENDOCYTE, INC. (US) | 2013-03-14 | — | — | US | claimed |
| WO-2011146707-A1 | IMPROVED PROCESS FOR A FOLATE-TARGETED AGENT | ENDOCYTE, INC. (US) | 2011-11-24 | — | — | WO | claimed |
| US-20230346752-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2023-11-02 | — | — | US | disclosed |
| US-20230293497-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2023-09-21 | — | — | US | disclosed |
| US-11717514-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230000836-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2023-01-05 | — | — | US | disclosed |
| US-11369590-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2022-06-28 | — | — | US | disclosed |
| US-11344623-B2 | Cholecystokinin B receptor targeting for imaging and therapy | PURDUE RESEARCH FOUNDATION (US) | 2022-05-31 | — | — | US | disclosed |
| EP-3656403-B1 | PREPARATION PROCESS OF PSMA BINDING LIGAND-LINKER CONJUGATES | PURDUE RESEARCH FOUNDATION (US) | 2022-05-11 | — | — | EP | disclosed |
| US-11318121-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2022-05-03 | — | — | US | disclosed |
| WO-2006012527-A1 | BIVALENT LINKERS AND CONJUGATES THEREOF | ENDOCYTE, INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| EP-1592457-A2 | VITAMIN RECEPTOR BINDING DRUG DELIVERY CONJUGATES | Endocyte, Inc. (US) | 2005-11-09 | — | — | EP | disclosed |
| US-20050002942-A1 | Minimized toxicity; eliminating pathogenic cell populations; synthesis; claimed intermediates | ENDOCYTE, INC. | 2005-01-06 | — | — | US | disclosed |
| WO-2004069159-A2 | VITAMIN RECEPTOR BINDING DRUG DELIVERY CONJUGATES | ENDOCYTE, INC. (US) | 2004-08-19 | — | — | WO | disclosed |
| EP-0445813-B1 | 7-(Diphenylmethyl)oxy-9a-methoxymitosane and the preparation and use thereof | BRISTOL MYERS SQUIBB CO (US) | 1995-08-02 | — | — | EP | disclosed |
| US-5352798-A | Intermediates for mitomycins; antitumor agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-10-04 | — | — | US | disclosed |
| US-5175303-A | Antitumor agents formed by reaction of diazodiphenylmethane and mitomycin C | BRISTOL-MYERS SQUIBB COMPANY (US) | 1992-12-29 | — | — | US | disclosed |
| US-5075454-A | Chemical intermediate, antitumor agent | BRISTOL-MYERS SQUIBB COMPANY (US) | 1991-12-24 | — | — | US | disclosed |
| EP-0445813-A1 | 7-(Diphenylmethyl)oxy-9a-methoxymitosane and the preparation and use thereof | Bristol-Myers Squibb Company (US) | 1991-09-11 | — | — | EP | disclosed |